Biogen (BIIB) PT Lowered to $385 at Guggenheim
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $222.67 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 2 | Down: 11 | New: 20
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 2 | Down: 11 | New: 20
Join SI Premium – FREE
Guggenheim lowered its price target on Biogen (NASDAQ: BIIB) to $385.00 (from $400.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight
- Morgan Stanley Assumes Wise plc (WISE:LN) (WPLCF) at Equalweight
- Morgan Stanley Upgrades Fintech Group AG (FTK:GR) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
